Mistletoe therapy, derived from the plant Viscum album, has emerged as a promising complementary approach in cancer care. Known for its immune-modulating and quality-of-life-enhancing effects, mistletoe therapy is used alongside conventional treatments like chemotherapy and radiation.
ABNOBA GmbH, a research-driven pharmaceutical company based in Pforzheim, Germany, is at the forefront of mistletoe-based medicinal development. Through its Indian partner, ABNOBA India, the company brings scientifically formulated mistletoe extracts to patients and clinicians across the country. Their preparations are standardized and carefully developed, ensuring safety, purity, and efficacy.
The therapy works by stimulating the immune system and promoting overall vitality. Many patients report improved energy levels, better sleep, reduced pain, and enhanced emotional well-being. Importantly, it can also help reduce the harsh side effects of conventional cancer treatments.
Mistletoe extracts are usually administered by injection under the skin. Treatment plans are personalized based on the type of cancer, stage, and patient response. ABNOBA’s medical team provides training and ongoing support to ensure optimal application and patient care.
While mistletoe therapy is not a substitute for standard oncology protocols, it complements them by focusing on the patient's holistic recovery. Backed by decades of clinical use in Europe, ABNOBA’s mistletoe products represent a reliable choice for integrative cancer therapy in India.
As more patients and practitioners turn to holistic care, mistletoe therapy is becoming a valuable component of supportive oncology.
